This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (29)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas M. Aaberg, Jr, MD; Harry W. Flynn, Jr, MD; Timothy G. Murray, MD
Miami, Fla

Arch Ophthalmol. 1994;112(1):18-19.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Approximately 85% of bacterial endophthalmitis cases are caused by gram-positive organisms, and treatment with intraocular vancomycin hydrochloride offers excellent coverage with a relatively low potential for retinal toxic effects. The antibiotic of choice for gram-negative coverage remains controversial because of the reported infrequent cases of macular infarction after intraocular administration of either gentamicin sulfate or amikacin sulfate.¹

See also pages 45 and 48

Ceftazidime is a third-generation cephalosporin with broad spectrum activity and particularly good coverage of gram-negative bacteria.² Furthermore, its antipseudomonal activity gives it an advantage over other third-generation cephalosporins.² Its use as an intraocular antibiotic has been recently investigated.³ We report the results of 13 cultureproven cases of microbial endophthalmitis treated with a combination of intraocular ceftazidime (2.25 mg), vancomycin hydrochloride (1 mg), and dexamethasone sodium phosphate (0.4 mg) via separate syringes (Table).

Report of Cases.

Of the 13 cases of microbial endophthalmitis, six . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?